Numerous RCTs have demonstrated the efficacy of AIT in both allergic asthma and rhinitis.

The aim of this study was to determine the efficacy of AIT in pts with allergic asthma according to pretreatment BEC.

This was a prospective study conducted in Greece (December 2021-November 2022), in a subset of 55 adults, with asthma and rhinitis.

Pts allocated in 2 groups Group A, n=30 with BEC?300celss/?l and Group B, n=25, with BEC?300 cells/?l), were initiated additional Subcutaneous Immunotherapy and followed for 48 weeks.

Efficacy endpoints included Asthma control test (ACT), Combined Symptoms and Medication (CSMS) scores and pre bronchodilator FEV1.

At the end of the follow up, only pts on the low BEC group, presented significantly higher improvements (ACT meanSD22.9±2.3 vs 13±2.7, p<0.001, preFEV1 meanSD1.94±0.450 vs 1.56±0.320 L/min, p<0.001), rhino-symptoms 0.4±1.2 vs 14.2±3 and medication score 0.3±0.9 vs 2.8± 0.1) in comparison to the respective values at baseline.

High BEC should always be considered in the decision to treat with AIT.